NATURAL PRODUCT RESEARCH AND DEVELOPMENT ›› 2019, Vol. 31 ›› Issue (增刊2): 120-126.doi: 10.16333/j.1001-6880.2019.S.019

• Article • Previous Articles     Next Articles

Antidiabetic mechanism of blueberry based on network pharmacology

 LUO Bei1,CHEN Shuang-kou1*,GUAN Tian-bing1,GUO Yin-ying1,JIE Hang2   

  1. 1Department of Chemistry,Chongqing University of Science and Technology,Chongqing 401331,China; 2 Institute of Medicinal Plant Cultivation,Chongqing 408435,China
  • Online:2019-12-28 Published:2019-12-30

Abstract: The aim of this study is to explore the material basis and mechanism of blueberry in the treatment of diabetes mellitus.Target genes of 11 active ingredients in blueberry were retrieved by using Batman-TCM research platform and compared with target genes of anti-diabetic drugs in GeneCards database.Target genes of anti-diabetic active ingredients in blueberry were screened out.GO enrichment and KEGG pathway analysis of target genes were carried out by String database,and protein interaction (PPI).Ingredient-target-pathway map was constructed by Cytoscape software.The results showed that seven components of blueberry have anti-diabetic effects,involving 48 targets such as INS and MAPK were found.KEGG and GO analysis showed that the main active components of blueberry could treat diabetes by controlling lipid metabolism,interfering with inflammation and interfering with insulin resistance.The antidiabetic effect of blueberry reflected the features of traditional Chinese medicine in multi-components,multi-targets and multi-pathways.Molecular docking results showed that six components were related to diabetes.Two important targets,INS and ADIPOQ,were well integrated.This paper validates the rationality of exploring the effective substance basis of natural products in network pharmacology based on reverse virtual screening,and points out the direction for further elucidating the pharmacological mechanism of blueberry in the treatment of diabetes mellitus and the development of blueberry.

Key words: blueberry, diabetes, network pharmacology, material basis

CLC Number: